找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Dose Finding and Beyond in Biopharmaceutical Development; Jingjing Ye,Ding-Geng Chen,Joseph C. Cappelleri Book 2025 The Editor(s) (if appl

[复制链接]
查看: 26589|回复: 46
发表于 2025-3-21 18:44:52 | 显示全部楼层 |阅读模式
书目名称Dose Finding and Beyond in Biopharmaceutical Development
编辑Jingjing Ye,Ding-Geng Chen,Joseph C. Cappelleri
视频video
概述Provides a natural discourse on the major advances over the last 20 years.Emphasizes case studies and best practices in dose-finding/dose-optimization in the evolving drug development paradigm.Supplie
丛书名称ICSA Book Series in Statistics
图书封面Titlebook: Dose Finding and Beyond in Biopharmaceutical Development;  Jingjing Ye,Ding-Geng Chen,Joseph C. Cappelleri Book 2025 The Editor(s) (if appl
描述.This book covers topics in 2 parts: 1) Review of FDA Guidance, 2) Novel Designs and Analyses. While covering basic principles of dose finding, this book details advancements made in drug development...Finding the right dose(s) is one of the most important objectives in new drug development. In Phase I clinical development, one of the objectives is to escalate test doses from low to high. The low doses should be safe, then escalate up to the maximally tolerable dose (MTD). Phase Ⅱ clinical trials then lower test doses to the minimal efficacious dose (MinED). Dose range of a study drug can be thought of as the doses between MinED and MTD. From this dose range, one or a few doses are selected for Phase Ⅲ confirmation. In practice, dose finding is a very difficult in every phase of clinical development for new drugs...The editors brought distinguished researchers and practitioners in biopharmaceuticals and universities, to discuss the statistical procedures, useful methods, and their novel applications in dose finding. The chapters in the book present emerging topics in dose-finding and related interdisciplinary areas. This timely book is a valuable resource to stimulate the developme
出版日期Book 2025
关键词Dose-finding designs; dose response clinical trials; clinical research; drug development; Project Optimu
版次1
doihttps://doi.org/10.1007/978-3-031-67110-4
isbn_softcover978-3-031-67112-8
isbn_ebook978-3-031-67110-4Series ISSN 2199-0980 Series E-ISSN 2199-0999
issn_series 2199-0980
copyrightThe Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl
The information of publication is updating

书目名称Dose Finding and Beyond in Biopharmaceutical Development影响因子(影响力)




书目名称Dose Finding and Beyond in Biopharmaceutical Development影响因子(影响力)学科排名




书目名称Dose Finding and Beyond in Biopharmaceutical Development网络公开度




书目名称Dose Finding and Beyond in Biopharmaceutical Development网络公开度学科排名




书目名称Dose Finding and Beyond in Biopharmaceutical Development被引频次




书目名称Dose Finding and Beyond in Biopharmaceutical Development被引频次学科排名




书目名称Dose Finding and Beyond in Biopharmaceutical Development年度引用




书目名称Dose Finding and Beyond in Biopharmaceutical Development年度引用学科排名




书目名称Dose Finding and Beyond in Biopharmaceutical Development读者反馈




书目名称Dose Finding and Beyond in Biopharmaceutical Development读者反馈学科排名




单选投票, 共有 0 人参与投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 23:38:18 | 显示全部楼层
发表于 2025-3-22 04:20:17 | 显示全部楼层
发表于 2025-3-22 07:35:41 | 显示全部楼层
发表于 2025-3-22 08:54:56 | 显示全部楼层
发表于 2025-3-22 16:27:36 | 显示全部楼层
https://doi.org/10.1007/978-3-642-92507-8luding leukemia 2023, kidney cancer, and melanoma (Siegel, CA Cancer J Clin 73(1):17–48, 2023). The development of targeted therapies, in particular, has dramatically altered the therapeutic landscape and improved outcomes for patients. Despite the seismic changes that have occurred in the field, so
发表于 2025-3-22 18:05:17 | 显示全部楼层
dbreaking initiative had fundamentally changed the oncology dose-finding paradigm: discouraging outdated conventions since the era of cytotoxic agents (identifying the maximum tolerated dose, MTD), and embracing new practices of identifying the optimal dosage among multiple doses based on totality o
发表于 2025-3-22 22:08:46 | 显示全部楼层
Bits, Bytes, Words and Numbers,e treatments, oncology trials need to start human research at a lower dose level and then move up and down through some dose levels in a process called dose finding that helps determine a safe dose level. The toxicity of these oncology drugs is always assumed to increase with dose. However, unlike i
发表于 2025-3-23 03:41:01 | 显示全部楼层
发表于 2025-3-23 06:27:12 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-20 06:49
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表